Exciting progress in the fight against cancer for both pets and humans On April 27, the US Food and Drug Administration (FDA) approved the application by our development partner, TVAX Biomedical, for Fast Track Designation for treatment of glioblastoma multiforme (GBM) with the immunotherapy technology ELIAS Animal Health is also using for treatment of osteosarcoma in dogs. Founded on the principle of translational medicine, ELIAS is especially pleased to have supported this major achievement. The efficacy and safety data from the previously completed canine osteosarcoma study conducted by ELIAS was an important component of the TVAX Fast Track application and we are pleased that the results of that study contributed to the FDA’s approval of the GBM Fast Track application. This is a significant accomplishment in that Fast Track Designation is not easily granted by the FDA and requires TVAX to provide evidence of its ability to successfully treat a [...]
Olathe, Kan., March 18, 2020 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announces the appointment of Tammy Ham to its Board of Directors. Ms. Ham is President of BioNOVUS Innovations LLC, a Kansas City-based firm committed to investing in individuals and organizations who are transforming healthcare, and Chief Executive Officer of CicloMed LLC, a developmental-stage pharmaceutical company focusing on unmet needs in human oncology. “Tammy Ham is an established leader in the healthcare field and a fantastic addition to the ELIAS Board of Directors,” said Tammie Wahaus, CEO of ELIAS. “Her experience in leading the development of pharmaceutical products will prove invaluable as we work toward licensure of our canine cancer immunotherapy.” “I am excited to join the ELIAS Board of Directors and to be part of our region’s vibrant animal health community,” said Ms. Ham. “I am impressed with [...]
Olathe, Kan., February 26, 2020 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announced today the appointment of Evan Courtemanche as Vice President of Manufacturing, and Jody Ehrhardt, as Director of Clinical Studies. Evan Courtemanche brings an extensive background in mammalian cell-culture manufacturing and supply chain functions in FDA and USDA-regulated therapeutics, and managing contract manufacturing relationships, both international and domestic. He currently oversees the biologics manufacturing processes and facility where the company’s USDA-regulated cancer immunotherapy is manufactured. Previously, Mr. Courtemanche served in manufacturing leadership and oversight roles for Aratana Therapeutics and Genzyme. Jody Ehrhardt, CCRC, brings more than 25 years of experience in clinical studies in both human and animal sciences. As the Director of Clinical Studies for ELIAS, she manages clinical study development, including protocol composition, study site recruitment and management, and regulatory reporting. Previously, she served as a [...]
ELIAS Animal Health has been named a 2020 Kansas City Startup to Watch by Startland News. The list of 10 startups is announced by Startland News each year and features innovative, entrepreneurial organizations making waves in the Kansas City area. “This nomination is a reflection of the hard work we’ve put in to bring our cancer immunotherapy to a broader audience,” said Tammie Wahaus, CEO of ELIAS. “I am excited to be included on this list of innovative companies in Kansas City, and look forward to a successful and impactful 2020.” Read the ELIAS Animal Health feature story, or view the full list startups on StartlandNews.com.
Olathe, Kan., June 6, 2019 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, and BodeVet, a Maryland-based company focused on the development of novel blood products for use in veterinary transfusion and regenerative medicine, have announced a joint effort to significantly expand the availability of ELIAS’ ECI® treatment for canine cancer via the mobile apheresis capabilities of BodeVet. Apheresis is a processing procedure that separates blood into different components and, in this case, yields the T cells critical to the ELIAS treatment protocol. Currently, there are twelve locations offering apheresis for pets. BodeVet offers a mobile service that will enable veterinary oncologists in most major cities in the United States to incorporate ECI® into their specialty hospital portfolio of oncology services, expanding beyond chemotherapy and radiation. Working together, ELIAS and BodeVet are committed to promoting animal health and welfare by developing [...]
Olathe, Kan., May 15, 2019 – ELIAS Animal Health, a Kansas City company dedicated to improving the treatment options for companion animals diagnosed with cancer, will be featured on Worldwide Business with kathy ireland®. Distributed internationally as sponsored content, you can view a highlight video below. The full interview will air on the following channels: Americas: Fox Business Network May 19, 2019, 5:30 p.m. EST Europe & Africa: Bloomberg EMEA Saturday, May 18, 2019, 7:30 p.m. GMT Asia: Bloomberg Asia Sunday, May 19, 2019, 10:30 a.m. D.F. and 3:00 p.m. HKT
Immunotherapy treatments are a hot topic in the area of treating human malignancies, which begs the question in the minds of many pet owners whose dogs or cats are diagnosed with cancer: where are these therapies for the four-legged members of the family? There are several barriers to making immunotherapies available in the veterinary space. However, a recent article in Veterinary Practice News by Hans Klingemann, MD, PhD, details some of these challenges and highlights the work being done by ELIAS Animal Health to overcome such barriers. “While patient survival outcomes using traditional cancer therapies such as chemotherapy and radiation have not significantly changed in the past couple of decades, they still remain the proven standard of care used by veterinary oncologists,” said Noe Reyes, Chief Medical Officer for ELIAS. “There is a significant unmet need for safer and more effective therapies to treat cancer. Immunotherapies, including adoptive T cell [...]
The University of Missouri recently shared progress on their work in helping advance ELIAS Animal Health’s treatment for bone cancer in dogs. The canine immunotherapy treatment is now available at MU, as well as at other universities and specialty hospitals across the country. Dr. Jeff Bryan, director of the MU's Comparative Oncology and Epigenetics Laboratory and principal investigator of the clinical trial, said of the treatment, “It’s the first time that dogs with osteosarcoma have experienced prolonged survival without receiving chemotherapy, which is really exciting.” Read the full announcement.
One in four dogs will be diagnosed with cancer in their lifetimes, and that’s only one of many diseases that can present a pet owner with a difficult health decision for their pet. This article highlights that an increasing number of pet owners are choosing to mitigate the financial challenges inherent in advanced treatments by purchasing pet insurance. According to Sarah A. Moser in a recent DVM360 article, the percentage of pets covered by insurance continues to grow, and looks to be accelerating with the millennial generation owning an ever increasing percent of total dogs and cats. Our inquiries indicate that ECI® from ELIAS is covered by many insurance companies today, when prescribed by a veterinarian. veterinarybusiness.dvm360.com/future-trend-millennials-could-be-boost-pet-insurance-needs
Olathe, Kan., Oct. 25, 2018 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announced results from its canine osteosarcoma immunotherapy trial at the 2018 Veterinary Cancer Society (VCS) Annual Conference. The study evaluating ELIAS’ Autologous Prescription Product, known as ECI® (ELIAS Cancer Immunotherapy) resulted in a median survival time (MST) of 415 days in animals completing therapy – compared to historical treatment outcomes associated with surgery alone (134 days1). These results will be included in the ELIAS submission to USDA-CVB during the fourth quarter. ELIAS intends to initiate a larger field safety and efficacy study in early 2019. “We are very encouraged by our osteosarcoma clinical trial results as we move towards commercialization of ECI® for the veterinary community, while continuing to explore our platform technology in other cancers such as lymphoma,” said Noe Reyes, D.V.M., ELIAS medical director. The trial [...]